Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
267
267 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- spartalizumabPDR001Phase 21 trial
Novartis · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
- SPVN20Phase 21 trial
SparingVision · Retinitis Pigmentosa (RP), Rod Cone Dystrophy
- SRP-1001ARO-DUX4Phase 21 trial
Sarepta Therapeutics, Inc. · Muscular Dystrophy, Facioscapulohumeral
- SRP-1003ARO-DM1Phase 21 trial
Sarepta Therapeutics, Inc. · Myotonic Dystrophy 1
- ST-920Phase 21 trial
Sangamo Therapeutics · Fabry Disease
- SXR1096Phase 21 trial
Sixera Pharma · Netherton Syndrome
- TAR-0520Phase 21 trial
Tarian Pharma · Hand and Foot Syndrome
- TGRX-814Phase 21 trial
Shenzhen TargetRx Co., Ltd. · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
- TISA-818-InjPhase 21 trial
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)
- TJO-087Phase 21 trial
Taejoon Pharmaceutical Co., Ltd. · Dry Eye Syndrome (DES)
- TRYP-0082Phase 21 trial
TRYP Therapeutics · Irritable Bowel Syndrome
- TSRA-196Phase 21 trial
Tessera Therapeutics, Inc. · Alpha-1 Antitrypsin Deficiency (AATD)
- TuspetinibHM43239Phase 21 trial
Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML
- VG801Phase 21 trial
VeonGen Therapeutics GmbH · Retinal Dystrophy Due to Biallelic ABCA4 Mutations, Stargardt Disease 1
- VP-001Phase 21 trial
PYC Therapeutics · Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease
- VTRU200Phase 21 trial
Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome
- WVE-006Phase 21 trial
Wave Life Sciences USA, Inc. · Alpha-1 Antitrypsin Deficiency
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.